太极集团中药为本发展战略研究

发布时间：2018-05-02 07:21

本文选题：太极集团 + 中药　；参考：《西南财经大学》2013年硕士论文

【摘要】：党的十一届三中全会以来,国家宏观经济取得大发展、大繁荣,中国GDP超欧赶日,世界第二经济体的殊荣实至名归。我国在全民医疗卫生及健康保障方面也取得了实质的进步,全民医保积极推进、新医改向纵深发展。人口老龄化加速、居民收入增长和健康意识增强,社会医药需求将快速增加,中国医药产业在2013至2022年将迎来持续高速发展的“黄金十年”。西药研发成本越来越高、研发时间越来越长,安全性日益突出,而以“自然疗法”提高生活品质为特点的天然药物产业将成为全球制药业最具发展前景的优势产业。中药产业是我国的特色传统产业,有深厚的历史底蕴和群众基础,老百姓对中医药的热情逐年高涨。中药因其确切疗效、治未病、综合调理、保健保养等特点恰好迎合老百姓对健康、长寿、美丽愿望的强烈需求,中药产业必将迎来快速发展的春天。我国中药产业50年前从零起步,经过艰苦创业、开拓发展到今天逐步壮大成熟,为保障人民群众的生命健康、提高生活质量作出了巨大贡献。进入21世纪,中医药产业在迅猛发展的同时,也不可避免地在药品注册、质量标准、专利保护、行业监管、研发生产、流通售后、参与国际竞争等方面出现了许多问题,这些问题如果不能及时有效地解决,必然会阻碍我国中医药产业的健康发展。太极集团经过近三十年的跨越式发展,从资产、产值都不足100万元,甚至濒临倒闭的涪陵地方企业,发展成今天资产过200亿元,拥有三家上市公司,位列医药工业前十强,中药制药企业行业第一的领先地位,成为中国医药产业链最为完整的医药企业之一。但是最近几年,快速发展的太极集团也遇到了体制僵化、管理落后、科研投入难以转化为生产力、财务及生产管理成本过高,经营效益低下、基础建设薄弱、核心竞争力不突出、资金链紧张、发展瓶颈限制、经营风险加大等问题,以上问题和不足严重影响到企业的健康发展,企业的千亿太极战略也只会停留在美好蓝图的层面上难以实现。本文对太极集团发展概况,战略环境与资源均衡做了系统科学的分析。得出太极集团在外部环境、内部资源与能力等关键因素方面有以下机会和优势：良好的社会经济发展基础；极大的中药产业吸引力和增长潜力：国家、地方强有力的中药产业扶持政策；科技进步、行业现代化发展趋势明显；太极集团极高的品牌知名度和行业美誉度；完备的中药产业链、市场营销网络建设；充足的科研、产品、土地、人力资源储备。同时也面临以下的挑战和劣势：行业技术瓶颈及国际认可质量标准难以建立；行业整体综合竞争力弱；国际天然植物药发展迅猛；现代中药产业进展缓慢；各种原材料、能源、劳动力等资源价格上涨；集团管理跟不上规模的扩张；没有建立科学高效的现代企业制度；集团负债过高、盈利和发展能力较低。综合分析太极集团EFE矩阵输出值为3.0,超过行业平均水平,表明公司目前面临相当好的外部环境,公司对于外部环境的发展变化也有足够的应变能力,对于公司中远期发展而言,应该制定一体化的积极扩张型发展战略；太极集团IFE矩阵输出值为2.35,略低于2.5,即低于行业平均水平,表明公司内部关键因素劣势大于优势。因此公司应该暂停多元化的发展战略,整合优势资源,练好内功,做大做强中药主业,提高自身核心竞争力,巩固行业优势地位。通过全面系统分析,科学论证,利用现代战略选择工具得出太极集团的正确发展战略是：“中药为本”!即以中药制造、销售为核心产业,实施中药大健康产业战略,构建中药全产业价值链。进一步确定集团关键战略环节为以冬虫夏草为代表的稀缺及贵细中药材的种植养殖及农户订单式生产收购,独家优势一、二平台中药工业产品的规模生产、全国推广,强大的渠道配送及终端零售网络。在工业产能布局上实行聚集式专业化生产战略,商业布局理念上强调终端为王发展战略,工商互动,为集团工业产品销售插上腾飞的翅膀。在做强主业、夯实内功的基础上加快推进中药现代化进程,并逐步进军中药大健康产业。产品结构方面构建T型产品线战略,市场布局方面采取市场分级、梯度推进的重点市场优先发展战略。同时分析认为太极集团只要做好资源与环境建设,改善组织结构,科学管理,确立好中药全产业链战略环节,科研与营销并重,加快集团现代中药产业进程,紧抓市场机会,通过战略联盟及有效的资本运作,太极集团十年战略目标一定会顺利实现。一个中国植物药制造业巨头一定会引领祖国中医药文化走出国门,走向世界!
[Abstract]:Since the third Plenary Session of the 11th CPC Central Committee, the national macro economy has achieved great development, great prosperity, China's GDP super European drive to catch up with the day, the second economy of the world is well known. China has also made substantial progress in the health care and health protection of the whole people, the health insurance of the whole people has been actively promoted, the new medical reform has developed in a deep way. With the increase of income and health awareness, the demand for social medicine will increase rapidly. China's pharmaceutical industry will usher in a "golden ten year", which continues to develop rapidly from 2013 to 2022. The cost of Western medicine and development is increasing, the time for R & D is growing, and the security is increasingly prominent, and natural medicine, characterized by "natural therapy", is characterized by the improvement of the quality of life. The industry will become the most promising industry in the global pharmaceutical industry. The traditional Chinese medicine industry is the traditional industry with a profound historical and mass base. The enthusiasm of the common people is rising year by year. The characteristics of traditional Chinese medicine, due to its exact effect, treatment, comprehensive conditioning and health care, meet the health, longevity and beauty of the common people. The Chinese traditional medicine industry will have a rapid development in the spring of the Chinese traditional medicine industry. The Chinese traditional medicine industry started from zero 50 years ago. It has made great contributions to the people's life and health and the quality of life. The Chinese medicine industry has developed rapidly in twenty-first Century. Inevitably, there are many problems in drug registration, quality standards, patent protection, industry supervision, research and development, circulation and after-sale, and participation in international competition. If these problems can not be solved in time and effectively, the healthy development of Chinese traditional Chinese medicine industry will be hindered.
After nearly thirty years of leapfrog development, Taiji Group has developed from assets, less than 1 million yuan in output value and even on the verge of bankruptcy of Fuling local enterprises. It has developed into today's assets over 20 billion yuan, and has three listed companies. It is the top ten of the pharmaceutical industry and the first leading position in the pharmaceutical industry of Chinese medicine, which has become the most complete chain of Chinese pharmaceutical industry. But in recent years, the rapid development of Taiji Group has also encountered problems such as rigid system, backward management, difficult transformation of scientific research input into productive forces, high cost of financial and production management, low operating efficiency, weak infrastructure, lack of core competitiveness, shortage of capital chain, restriction of development bottleneck and increasing operational risk. The above problems and deficiencies seriously affect the healthy development of enterprises. The 100 billion Taiji strategy of enterprises will only remain at the level of the beautiful blueprint.
This paper makes a systematic and scientific analysis of the development of Taiji group, the strategic environment and the balance of resources, and concludes that the Taiji Group has the following opportunities and advantages in the aspects of external environment, internal resources and ability, such as the good social and economic development foundation, the great attraction and growth potential of the traditional Chinese medicine industry: the country and the local power The traditional Chinese medicine industry support policy; scientific and technological progress, the development trend of industry modernization is obvious; Taiji Group is very high brand awareness and industry reputation; complete Chinese medicine industry chain, marketing network construction; sufficient scientific research, products, land, human resources reserve. Meanwhile, the following challenges and disadvantages are also faced: industry technical bottleneck And the international accredited quality standards are difficult to be established; the overall competitiveness of the industry is weak; the development of international natural plant drugs is swift and violent; the development of modern traditional Chinese medicine industry is slow; the prices of various raw materials, energy, labor and other resources have risen; the management of the group can not keep up with the expansion of the scale; the scientific and efficient modern enterprise system has not been established; the group liability is not established. The EFE matrix output value of the Taiji Group is 3, exceeding the average level of the industry, which indicates that the company is facing a fairly good external environment and the company has sufficient strain ability for the development and change of the external environment. For the medium and remote development of the company, the integrated and active expansion should be formulated. Development strategy: the IFE matrix output value of Taiji Group is 2.35, slightly lower than 2.5, that is, lower than the industry average, which indicates that the company's internal key factors are more inferior than the advantages. Therefore, the company should suspend the diversification strategy, integrate the advantage resources, practice the internal skills, make the major Chinese medicine main industry, improve the core competitiveness of the company, and consolidate the advantages of the industry. Position.
Through comprehensive systematic analysis, scientific demonstration and the use of modern strategic choice tools, the correct development strategy of Taiji Group is as follows: "Chinese medicine is the base", which is made of traditional Chinese medicine, sales as the core industry, the implementation of Chinese traditional Chinese medicine industry strategy and the construction of the whole industry value chain of traditional Chinese medicine. The scarcity of the representative, the cultivation of traditional Chinese medicinal materials and the purchase and purchase of farmers' order type production, the exclusive advantage one, the scale production of the two platform Chinese medicine industrial products, the nationwide promotion, the powerful channel distribution and the terminal retail network. In the industrial production layout, the centralized and specialized production strategy is implemented, and the business layout concept emphasizes the terminal for Wang Fa. On the basis of strengthening the main industry and consolidating the internal work, we will accelerate the process of modernization of Chinese medicine on the basis of strengthening the main industry and consolidating the internal work, and step into the big health industry of traditional Chinese medicine. The product structure of the product line is built on the T product line strategy, the market layout takes market classification, and the key market with gradient promotion is the priority market priority. At the same time, it is believed that Taiji group should do well in the construction of resources and environment, improve the structure of the organization, scientific management, establish the strategic link of the whole industry chain of traditional Chinese medicine, attach importance to scientific research and marketing, accelerate the process of the modern traditional Chinese medicine industry, grasp the market opportunity, through the strategic alliance and effective capital operation, the ten year strategy of Taiji group. A Chinese herbal medicine manufacturing giant will lead the Chinese medicine culture to the world.

【学位授予单位】：西南财经大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F272;F426.72

【参考文献】